Treatment of multiple myeloma
JF San Miguel, JB Creixenti, R García-Sanz - Haematologica, 1999 - haematologica.org
BACKGROUND AND OBJECTIVE: Multiple myeloma (MM) accounts for about 10% of all
hematologic malignancies. The standard treatment with intermittent courses of melphalan …
hematologic malignancies. The standard treatment with intermittent courses of melphalan …
Total therapy with tandem transplants for newly diagnosed multiple myeloma
B Barlogie, S Jagannath, KR Desikan… - Blood, The Journal …, 1999 - ashpublications.org
Abstract Between August 1990 and August 1995, 231 patients (median age 51, 53% Durie-
Salmon stage III, median serum β-2-microglobulin 3.1 g/L, median C-reactive protein 4 g/L) …
Salmon stage III, median serum β-2-microglobulin 3.1 g/L, median C-reactive protein 4 g/L) …
[HTML][HTML] The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review
T Hahn, JR Wingard, KC Anderson… - Biology of Blood and …, 2003 - Elsevier
Evidence supporting the role of hematopoietic stem cell transplantation (SCT) in the therapy
of multiple myeloma (MM) is presented and critically evaluated in this systematic evidence …
of multiple myeloma (MM) is presented and critically evaluated in this systematic evidence …
Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma
DG Maloney, AJ Molina, F Sahebi… - Blood, 2003 - ashpublications.org
The full potential of a graft-versusmyeloma effect after allogeneic hematopoietic cell
transplantation (HCT) for patients with multiple myeloma (MM) has not been realized …
transplantation (HCT) for patients with multiple myeloma (MM) has not been realized …
Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population …
S Lenhoff, M Hjorth, E Holmberg… - Blood, The Journal …, 2000 - ashpublications.org
High-dose therapy has become a common treatment for myeloma. The objectives of this
study were to estimate in a prospective, population-based setting the impact on survival of …
study were to estimate in a prospective, population-based setting the impact on survival of …
Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation
HM Lokhorst, A Schattenberg… - Blood, The Journal …, 1997 - ashpublications.org
Donor leukocyte infusions (DLI) can induce sustained remissions in patients with acute and
chronic myeloid leukemia who relapse after allogeneic bone marrow transplantation (allo …
chronic myeloid leukemia who relapse after allogeneic bone marrow transplantation (allo …
Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients
A Palumbo, S Triolo, C Argentino… - Blood, The Journal …, 1999 - ashpublications.org
A clinical relationship between dose-intensity of melphalan and response rate has been
demonstrated in multiple myeloma. Promising results have been reported after 200 mg/m2 …
demonstrated in multiple myeloma. Promising results have been reported after 200 mg/m2 …
Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma
G Martinelli, C Terragna, E Zamagni… - Journal of Clinical …, 2000 - ascopubs.org
PURPOSE: To assess the clinical relevance of minimal residual disease (MRD) in patients
with multiple myeloma (MM), 50 patients were monitored while they were in complete …
with multiple myeloma (MM), 50 patients were monitored while they were in complete …
Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study
A Riccardi, O Mora, C Tinelli, D Valentini… - British Journal of …, 2000 - nature.com
We conducted a randomized trial to evaluate whether melphalan-prednisone (MPH-P)
treatment administered just after diagnosis improves survival of stage I multiple myeloma …
treatment administered just after diagnosis improves survival of stage I multiple myeloma …
[HTML][HTML] Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed …
JJ Lahuerta, MV Mateos, J Martínez-López… - …, 2010 - ncbi.nlm.nih.gov
Background The aim of this study was to compare the long-term safety and efficacy of oral
busulfan 12 mg/kg plus melphalan 140 mg/m 2 and melphalan 200 mg/m 2 as conditioning …
busulfan 12 mg/kg plus melphalan 140 mg/m 2 and melphalan 200 mg/m 2 as conditioning …